<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704985</url>
  </required_header>
  <id_info>
    <org_study_id>DEKA-1</org_study_id>
    <nct_id>NCT05704985</nct_id>
  </id_info>
  <brief_title>Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors</brief_title>
  <official_title>Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DEKA Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DEKA Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC)&#xD;
      DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or&#xD;
      radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate DK210(EGFR) as monotherapy and combination in subjects with advanced&#xD;
      solid EGFR expressing cancers with documented progressive disease after at least one line of&#xD;
      systemic treatment (staging performed by local standard).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2023</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) with DK210 (EGFR)</measure>
    <time_frame>Minimum of 90 days from initiation of experimental therapy</time_frame>
    <description>Based on toxicities observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify recommended dose of DK210 (EGFR)</measure>
    <time_frame>Initiation of therapy up to day 90</time_frame>
    <description>Based on toxicities observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation, chemotherapy, or checkpoint blockers in Parts B, C, D</measure>
    <time_frame>Minimum of 90 days from initiation of experimental therapy</time_frame>
    <description>Based on toxicities observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Initiation of therapy up to approximately 12 months</time_frame>
    <description>Overall response rate (ORR) will be based on clinical examination and investigator review of radiographic images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response rate at 9 weeks</measure>
    <time_frame>Initiation of therapy through Day 63</time_frame>
    <description>Based on investigator clinical examination and review of radiographic images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free (PFS)</measure>
    <time_frame>Study Day 1 until the date of first documented progression or date of death from any cause, assessed up to approximately 24 months</time_frame>
    <description>Time from first dose of DK210 (EGFR) to first documentation of clinical or radiographic disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Time from first dose of DK210 (EGFR) to the time of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of DK210 (EGFR) will be determined at various time points</measure>
    <time_frame>From initiation of treatment through 12 months (every 9 weeks)</time_frame>
    <description>Concentration vs time and standard pharmacokinetic (PK) parameters will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum will be assayed for the presence of anti-DK210 (EGFR) antibodies</measure>
    <time_frame>From initiation of treatment through 12 months (every 9 weeks)</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points</measure>
    <time_frame>From initiation of treatment through day 63</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of proinflammatory cytokines such as IL-6, IL-10, TNFa, IL-1b, and interferon (IFN)-g will be assessed at various time points</measure>
    <time_frame>From initiation of treatment through 12 months (every 9 weeks)</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Gynecologic Cancer</condition>
  <condition>Skin Cancer</condition>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>DK210 (EGFR) Monotherapy (Dose escalation and expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DK210 (EGFR) will be administered as monotherapy three times per week via subcutaneous (SC) administration. Dose will be escalated from 0.025 mg/kg to 0.3 mg/kg or until unacceptable toxicity, disease progression, or withdrawal of consent. An expansion cohort at the optimal dose will be enrolled in parallel with the combination arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DK210 (EGFR) + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients with good tolerance of first line systemic therapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with second-line intravenous (IV) chemotherapy until unacceptable toxicity, disease progression, or withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DK210 (EGFR) + radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients with need of palliative radiation, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with short course radiation therapy (10 fractions or less) until unacceptable toxicity, disease progression, or withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DK210 (EGFR) + immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients with good tolerance of first line immunotherapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with intravenous (IV) immune checkpoint blockers until unacceptable toxicity, disease progression, or withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DK210 (EGFR)</intervention_name>
    <description>Solution for SC administration</description>
    <arm_group_label>DK210 (EGFR) + chemotherapy</arm_group_label>
    <arm_group_label>DK210 (EGFR) + immunotherapy</arm_group_label>
    <arm_group_label>DK210 (EGFR) + radiation</arm_group_label>
    <arm_group_label>DK210 (EGFR) Monotherapy (Dose escalation and expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Short regimen radiation therapy (10 fractions or less)</description>
    <arm_group_label>DK210 (EGFR) + radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune checkpoint blockers</intervention_name>
    <description>IV administration of approved PD1 blocker</description>
    <arm_group_label>DK210 (EGFR) + immunotherapy</arm_group_label>
    <other_name>Pembrolizumab</other_name>
    <other_name>Nivolumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Single agent or combination of not more than two</description>
    <arm_group_label>DK210 (EGFR) + chemotherapy</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>Carboplatin</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Fluorouracil</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Life expectancy of &gt;3 months according to the investigator's judgment&#xD;
&#xD;
          -  Solid tumors known for response on Il-2 or Il-10 and/or high expression of EGFR like&#xD;
             all Non-small cell Lung, Skin, Head and Neck, Colon, Kidney, Bladder, Pancreatic&#xD;
             cancers and all squamous cell carcinoma of other organs can be included with a&#xD;
             classical histology report, specific EGFR expression or amplification reports are&#xD;
             needed for other solid tumor types like gynecologic, prostate or triple negative&#xD;
             breast cancer&#xD;
&#xD;
          -  Measurable disease, defined as at least one (non-irradiated) lesion measurable on&#xD;
             CT/MRI or bone scan as defined by RECIST 1.1.&#xD;
&#xD;
          -  Progressive disease (PD) at study entry defined as one or more of the following&#xD;
             criteria:&#xD;
&#xD;
          -  Clinical PD with performance decline, clinical symptoms and/or observed tumor growth&#xD;
&#xD;
          -  PD documented with imaging showing at least 20% growth (largest diameter) and/or new&#xD;
             lesions&#xD;
&#xD;
          -  Adequate cardiovascular, hematological, liver, and renal function.&#xD;
&#xD;
          -  Subjects have failed one or more lines of systemic therapy and have not been operated&#xD;
             on or receiving anti-cancer medication for at least 4 weeks.&#xD;
&#xD;
          -  Males and females of childbearing potential must agree to use effective contraception&#xD;
             starting prior to the first day of treatment and continuing during treatment&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with documented diffuse peritoneal disease or persistent abundant ascites&#xD;
&#xD;
          -  Subjects with known prolonged QtC interval&#xD;
&#xD;
          -  Concomitant or recent (&lt;4 weeks or 5 half-lives of the last treatment, whichever is&#xD;
             shorter) treatment with agents with anti-tumor activity, including immunotherapies, or&#xD;
             experimental therapies. Bone treatments and supportive care can be continued&#xD;
&#xD;
          -  Major surgery within 4 weeks, Radiation therapy for the treatment of metastases within&#xD;
             less than 3 weeks (if single fraction of radiotherapy, then within 2 weeks) and&#xD;
             radionuclide therapy for the treatment of metastases within 4 weeks prior to screening&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing and&#xD;
             uncontrolled infection (TBC, COVID or HIV patients treated with at least two&#xD;
             anti-retroviral drugs and control of their infection with at least 500 /mm3 CD4+&#xD;
             T-cells in their blood and patients cured from Hepatitis B or C (i.e negativity of&#xD;
             PCR) and liver function compatible with eligibility criteria are allowed to&#xD;
             participate), multiple myeloma, multiple sclerosis, myasthenia gravis, or psychiatric&#xD;
             illness/social situations that, in the opinion of the investigator, would limit&#xD;
             compliance with study requirement&#xD;
&#xD;
          -  Any other conditions that, in the investigator's opinion, might indicate the subject&#xD;
             to be unsuitable for the study&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Moser, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>DEKA Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DEKA Biosciences</last_name>
    <phone>920-227-5115</phone>
    <email>clinical@dekabiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Orr, MD</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>Douglas Orr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryann Poole</last_name>
      <phone>703-280-5390</phone>
      <email>mpoole@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alex Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 19, 2023</study_first_submitted>
  <study_first_submitted_qc>January 27, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>May 12, 2023</last_update_submitted>
  <last_update_submitted_qc>May 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytokine</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin 2</keyword>
  <keyword>IL-10</keyword>
  <keyword>Interleukin 10</keyword>
  <keyword>Oncology</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>DK210(EGFR)</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>DEKA</keyword>
  <keyword>DEKA Biosciences</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time, IPD sharing has not been defined and/or decided if it will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

